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844.e1 The Journal of Thoracic and CarObjectives: Transplantation is limited by a lack of human organ donors. Organs
derived from animals, most likely the pig, represent a potential solution to this
problem. For the heart, 90-day median graft survival of life-supporting pig hearts
transplanted to nonhuman primates has been considered a reasonable standard for
entry into the clinical arena. Overcoming the immune barrier to successful cardiac
xenotransplantation is most appropriately first explored with the non–life-supporting
heterotopic model.
Methods: We performed a series of 7 heterotopic heart transplantations from CD46
transgenic pigs to baboons using a combination of therapeutic agents largely
targeted at controlling the synthesis of anti-pig antibodies. Rituximab (anti-CD20)
and Thymoglobulin (rabbit antithymocyte globulin [ATG]; SangStat Medical Corp,
Fremont, Calif) were used as induction therapy. Baseline immunosuppression
consisted of splenectomy, tacrolimus, sirolimus, steroids, and TPC (an anti-Gal
antibody therapeutic). Rejection events were not treated.
Results: By using Kaplan-Meier analysis, median graft survival was 96 days (range,
15-137 days; 95% confidence interval, 38-99 days). Only 2 grafts were lost as a
result of rejection, as defined by cessation of graft palpation. There was no evidence
of a consumptive coagulopathy, infectious complications were treatable, and no
posttransplantation lymphoproliferative disorders occurred. No cellular infiltration
was observed.
Conclusions: This study reports the longest median survival to date (96 days) of pig
hearts transplanted heterotopically into baboons. Duplication of these results in the
orthotopic life-supporting position could bring cardiac xenotransplantation to the
threshold of clinical application.
Transplantation has become the preferred therapy for the treatment of end-stage organ failure. This success has unmasked a substantial gap between thenumber of patients who could benefit from a transplant and those who
actually receive one. In the United States it has been calculated that on an annual
basis 40,000 patients in congestive heart failure could benefit from a heart trans-
plantation, yet fewer than 2500 transplantations are performed, a number that has
not substantially changed in the last 10 years.1,2 This discrepancy between supply
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one of which is the use of animals as organ donors. The
animal of choice for clinical application of xenotransplan-
tation is currently considered to be the pig because of its
size, physiologic compatibility, and breeding characteristics
and the potential for genetic modification. The current ma-
jor limitation to clinical xenotransplantation is immunologic
rejection.3 A 90-day median survival of life-supporting or-
thotopic pig heart transplants in nonhuman primates has
been proposed as a prerequisite for clinical application.4 A
first step in achieving this goal is to define immunosuppres-
sive regimens that control the xenograft immune response
by using non–life-supporting heterotopic transplants.
Pig organs, when transplanted to primates, are rapidly
rejected because of the presence of recipient antibody that
recognizes a carbohydrate epitope, galactose 1-3 galactose
(-Gal), which is present on glycoproteins and glycolipids
on the pig endothelium.5 This rejection process, hyperacute
rejection, can be routinely overcome by the removal of
anti-Gal antibody6 or the inhibition of the complement
cascade by the use of transgenic pigs that express human
complement regulatory proteins.7-9 When hyperacute rejec-
tion is blocked, grafts are usually lost within a few days to
weeks through a process called delayed xenograft rejection
(DXR).10-12 DXR is thought to be mediated by both preex-
isting and induced anti-Gal antibodies and is not controlled
by the currently available immunosuppressive agents.13,14
We have previously shown that an -Gal–polyethylene
glycol conjugate (TPC) can block the anti-Gal immune
response in primates.15,16 This led us to hypothesize that the
use of such a conjugate, together with a regimen of immu-
nosuppressive agents targeted to block an antibody-
mediated immune response, would result in prolonged graft
survival of a transgenic pig heart transplanted heterotopi-
cally to the baboon.
In a previous protocol we had used an immunosuppressive
regimen consisting of rituximab (anti-CD20 monoclonal anti-
body), tacrolimus, sirolimus, steroids, enoxaparin (Lovenox),
and TPC.17 This earlier study obtained a median graft survival
of 76 days; however, excessive use of ATG to treat presump-
TABLE 1. Summary of transplantation results
Recipient
Duration
(d)
Graft
failure
Palpation
score
D
gra
1 15 No 5
2 38 No 6
3 54 No 6
4 64 No 6
5 96 Yes 0
6 99 No 5
7 137 Yes 0DXR, Delayed xenograft rejection; D, diffuse; NEG, negative; F, focal; UR, unrea
The Journal of Thoracic ative rejection episodes led to the development of infectious
complications, including frequent bacterial sepsis, fatal emer-
gence of baboon cytomegalovirus (CMV), and posttransplan-
tation lymphoproliferative disorder (PTLD). To improve on
this experience, we have adopted a simplified immunosuppres-
sive regimen using ATG and rituximab only for induction
therapy, and rejection episodes were not treated. Our current
protocol uses no postoperative anticoagulants and resulted in
96-day median graft survival. This protocol showed no evi-
dence of perioperative consumptive coagulopathy, was free of
fatal infectious complications, and showed no evidence of
CMV or PTLD. This result is the longest reported median
survival of pig hearts transplanted into baboons and represents
a significant step toward the onset of clinical
xenotransplantation.
Methods
Donors and Heterotopic Heart Transplantation
Pig donors were transgenic for the human complement regulatory
protein CD46 and have been described in detail.18 Standard hete-
rotopic abdominal pig-to-baboon heart xenotransplantation was
performed.19,20 All animals were housed and received humane
care in accordance with the standards established by the Institu-
tional Animal Care and Use Committee of the Mayo Clinic and
Foundation and as described in the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory An-
imal Resources and published by the National Institutes of Health
(NIH publication no. 86-23, revised 1985).
Immunosuppression
The day of transplantation is considered postoperative day (POD)
0. The immunosuppressive regimen consisted of TPC at 50 mg/kg
every 3 days for a total of 6 doses before transplantation and daily
after transplantation until day 30. After day 30, TPC was admin-
istered once every 3 days. Induction therapy consisted of Thymo-
globulin (rabbit antithymocyte globulin [ATG]; SangStat Medical
Corp, Fremont, Calif) at 1.5 mg/kg starting at day 2 for a total of
5 doses and rituximab (Genentech Inc, South San Francisco, Calif)
at 19 mg/kg weekly starting at day 7 for a total of 4 doses.
Maintenance immunosuppression consisted of tacrolimus (Pro-
graf; Fujisawa Healthcare Inc, Deerfield, Ill) to achieve a trough
IgM IgG C5b Cause of death
D2 NEG F1 Atrial rupture
F2 NEG NEG Ventricular rupture
D2 NEG NEG Iatrogenic
D2 F2 NEG Renal failure
UR UR UR NA: elective explantation
D3 D2 NEG Pulmonary embolism
UR UR UR NA: elective explantationXR
de
3
1
1
1
4
4
4dable; NA, not applicable.
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ries Inc, Philadelphia, Pa) to achieve a trough level of 10 to 20
ng/mL, and a tapering dose of steroids. After POD 60, targeted
trough levels of tacrolimus were reduced to 10 to 15 mg/mL.
Splenectomy was performed on day 7 before the first dose of
rituximab.
Graft Monitoring
Graft survival was estimated as either the last day of detectable
palpation or animal mortality, whichever occurred first. Palpation
was scored on a scale of 0 to 6, with 6 indicating the strongest
pulsation. Cessation of palpation was confirmed by means of
echocardiography and intramyocardial electrography, as previ-
ously described.21
Additional methods for histologic analysis, anti-Gal enzyme-
linked immunosorbent assay, infectious disease management, and
statistical analysis can be found in the online-only Appendix E1.
Results
Duration of Graft Function
Seven heterotopic heart transplantations were performed, and
the length of survival ranged from 15 to 137 days (Table 1).
Two grafts succumbed to rejection on days 96 and 137, as
defined by a cessation of palpation and a lack of contractility at
echocardiography. All other grafts (n  5) were still contract-
Figure 1. Hematologic analysis of transplant recipients
cell counts; D, analysis of CD20 and CD40 lymph
transplantation, and at the time of rejection or recipie
shown. Comparable samples from recipients 4 and
excluded from this analysis. Control represents the pro
baboon.ing vigorously, with a palpation score of 6 (n  3) or 5 (n 
844.e3 The Journal of Thoracic and Cardiovascular Surgery ● Se2) confirmed by means of echocardiography near the time of
recipient mortality. Two recipients died of hemorrhage (one on
day 15 from rupture of a thrombosed atrium and another on
day 38 from left ventricular rupture, likely caused by coronary
embolism from a thrombosed left heart and donor aorta). One
recipient died with a functioning graft on day 64 of renal
insufficiency. This recipient exhibited increasing serum creat-
inine levels at the time of death, and histology of the baboon
kidney showed widespread acute tubular necrosis at necropsy.
One recipient died from a pulmonary embolism on day 99. The
last recipient died on day 54 after gastric feed was injected
intravenously in error. Because this recipient had a vigorously
contracting pig heart at the time of death and died for reasons
clearly unrelated to the immune response to the xenograft, we
considered the duration of organ function as censored at the
time of death for this animal. The observed durations of organ
function ranged from 15 to 137 days, and the Kaplan-Meier
estimation of median duration of organ function was 96 days
(95% confidence interval, 38-99 days).
Hematology
Immediately after transplantation, there was no evidence of
thrombocytopenia associated with consumptive coagulopa-
latelet counts; B, hematocrit value; C, total white blood
s in mesenteric lymph nodes on POD 0, the day of
ath (Table 1). Data from recipients 1, 2, 3, 6, and 7 are
re not obtained, and therefore these animals were
n of CD20 and CD40 lymphocytes from an untreated: A, p
ocyte
nt de
5 we
portiothy (Figure 1, A). Most recipients maintained platelet levels
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period. The only exception to this was the graft lost to atrial
rupture on day 15 that showed a precipitous platelet de-
crease associated with the hemorrhage. The recipient that
died on POD 54 exhibited chronic low platelet levels be-
ginning on POD 11, with no adverse effects on graft func-
tion or histology at necropsy. In general, the hematopoietic
function in the baboons remained good, with a hematocrit
value of approximately 30% (Figure 1, B). Erythropoietin
was not used in any of these recipients. Blood transfusions
were given to 4 of the recipients. In 2 instances (recipients
1 and 2) transfusions were in direct response to bleeding
episodes that preceded rupture of the graft. In another case
a transfusion was given after detecting and repairing an
apical aneurysm in the left ventricle of the xenograft in
recipient 7 (POD 43). The other transfusion was given to
recipient 3 (POD 21) in response to low hemoglobin levels.
Circulating white blood cell (WBC) counts decreased early
after transplantation, presumably in response to ATG treat-
ment (Figure 1, C). Subsequently, WBC counts rebounded
and remained stable at approximately 2 to 8  106/mL
throughout the transplantation period. Differential analysis
of whole WBCs indicated that neutrophils constituted ap-
proximately 85% of the cells, with lymphocytes making up
approximately 9%.
Rituximab (anti-CD20) induction on days 7, 0, 7, and
14 was highly effective in depleting circulating B cells but
appeared to be less effective at eliminating B cells within
lymphoid tissues. We used anti-CD20 and CD40 antibodies
to identify baboon B cells. Reagents that detect baboon
CD19 were not available. In a previous analysis, all B cells
in unmanipulated baboons were double positive for these
markers. After anti-CD20 induction therapy, there was a
complete depletion of circulating B cells for the duration of
the transplantation (data not shown). Depletion of CD20
cells was also apparent in the mesenteric lymph nodes on
the day of transplantation; however, positive staining with
anti-CD40 suggested that B cells were still present and that
these cells were either coated with rituximab, thus prevent-
ing the binding of a second anti-CD20 monoclonal anti-
body, or alternatively had modulated expression of the
CD20 surface antigen. A similar situation was observed in
necropsy samples in which, except for recipient 6, the
proportion of CD20 lymph node cells was reduced, but
CD40 cells were in proportions that are comparable with
those seen in untreated lymph nodes (Figure 1, D).
Histologic Analysis
The endpoint of graft failure under these experimental con-
ditions was DXR, which was characterized histologically as
coagulative necrosis with large areas of ischemic tissue and
microvascular thrombosis (Table 1). Generally, there was
no thrombosis of the larger blood vessels, which remained
The Journal of Thoracic apatent (Figure 2, A). There was no evidence of a cellular
infiltrate in any graft. Transplant vasculopathy, character-
ized by intimal thickening of the arterial wall, was not a
prominent feature of rejection and was detected in only a
single vessel of one recipient. Long-surviving grafts with
vigorous contractility exhibited well-preserved myocardium,
with only focal regions of tissue damage, ranging from mild
edema or ischemia to myocyte necrosis (Figure 2, B).
Immunohistochemistry of frozen sections was interpret-
Figure 2. Xenograft histology. A, Xenograft of recipient 6 ex-
planted on POD 99, when the recipient died of a pulmonary
embolism. The graft shows extensive DXR with large regions of
coagulative myocyte necrosis. B, Xenograft of recipient 4 that
died of renal failure on POD 64. The section shows minimal
evidence of DXR. There is one small focus of myocardium with
coagulative necrosis (*) surrounded by well-preserved myocar-
dium. (Hematoxylin and eosin, original magnification 100.)able in 5 of the 7 grafts and consistently showed the depo-
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diffuse staining with a trend toward more intense labeling in
the grafts that showed evidence of greater damage (Table 1).
Staining for IgG (Figure 3, B and D) ranged from negative
in 3 of the grafts to a diffuse staining in 1 graft. The trend
again was to more intense and widespread staining in the
more damaged grafts. Complement deposition was either
absent (n  4) or weakly positive (n  1).
Infectious Complications
In our previously published transplantation series, we had
observed widespread activation of baboon CMV with se-
vere clinical manifestations.17 In the current series of trans-
plantations, there was no evidence of CMV. Whether this
was due to a lack of activation of the virus or the presence
of effective prophylaxis with ganciclovir cannot be estab-
lished. No PTLD, a transplant-related malignancy associ-
Figure 3. Immunohistochemical staining of explanted
animal shown in Figure 2, A, with severe DXR, and C a
2, B, with minimal DXR. Intense diffuse staining of end
IgG is seen in A and B. Diffuse moderate staining of e
staining of endothelial cells by IgG is seen in D. Arrow
100 for each panel, 200 for IgG insets.)ated with infection by a -herpesvirus, was seen either
844.e5 The Journal of Thoracic and Cardiovascular Surgery ● Segrossly or histopathologically at necropsy. No fungal infec-
tions were seen. Bacterial infections (detected in 3/7 recip-
ients) were reversible with appropriate antibiotic therapy.
Anti-Gal Antibody
Serum anti-Gal antibodies were measured throughout the
course of the transplantation procedure and also after explan-
tation. Before transplantation, TPC reduced both anti-Gal IgG
and IgM to background levels, and these levels were main-
tained during the transplantation (data not shown). Postexplan-
tation induction of anti-Gal antibodies could be determined in
only one animal (recipient 7) that rejected the xenograft on
POD 137 (Figure 4). In the absence of TPC but during basal
immunosuppression, there was no increase in postexplantation
anti-Gal IgG consistent with a lack of sensitization. Serum
anti-Gal IgM levels rebounded slowly after graft removal;
however, they only attained approximately 40% of the baseline
ac xenografts. A and B are from recipient 6, the same
are from recipient 4, the same animal shown in Figure
lial cells in remaining viable myocardium by IgM and
elial cells with IgM is seen in C, and focal moderate
ghlight areas shown as insets (Original magnificationcardi
nd D
othe
ndoth
s hilevel. These observations are consistent with our previous
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induction of an anti-Gal antibody response was severely
restricted.22
Discussion
In this study long-term graft function of heterotopic pig-to-
baboon cardiac transplants was achieved with only 2 of the
7 grafts lost because of rejection. Median graft survival in
this prospectively defined group of animals was 96 days
(range, 15-137 days; n  7), showing progress from our
previous study17 and a substantial improvement over previ-
ously reported median survivals seen by others.23,24 For
xenotransplantation to progress to clinical application, ac-
ceptable immunosuppressive regimens capable of control-
ling the immune response to the graft must be defined. We
have used basal immunosuppression consisting of tacroli-
mus, sirolimus, and steroids. This combination of drugs has
shown efficacy in preclinical primate allograft models25 and
is used clinically for presensitized patients.26 It is important
to note, however, that the efficacy range for tacrolimus and
sirolimus in baboons is not established. In our earlier studies
that did not use ATG at the time of transplantation, the
blood trough levels for tacrolimus and sirolimus were main-
tained within the range normally used in human subjects.
Under these conditions, anti-Gal immune responses were
minimized, but median organ survival was limited to 15
days (range, 4-53 days).21,22 In a subsequent study, basal
immunosuppression was increased to the range used in the
current study, resulting in a median duration of xenograft
heart function of 76 days (range, 55-113 days; n  9).17
These experiments, however, also included weekly dosing
with rituximab and the treatment of multiple presumptive
rejection episodes with ATG. As a result, the overall level
of immunosuppression in these transplants was considered
excessive and resulted in significant bacterial27 and viral
infections and 2 cases of PTLD. In the present study we
omitted the treatment of presumptive rejection episodes and
used ATG and rituximab as induction therapy only. This
reduction of immunosuppression had no negative effect on
graft survival and appears to have reduced the significant
infectious complications seen previously, although more
effective antiviral prophylaxis might also have contributed
to the absence of CMV emergence. This suggests to us that
the presumptive rejection episodes treated in our previous
study were probably falsely identified and underscores the
need for effective diagnostic and therapeutic modalities for
DXR. Furthermore, although we cannot as yet determine
whether the increased levels of tacrolimus and sirolimus, the
induction therapy with ATG, or a combination was the key
to longer graft survival, it seems likely that repeated ATG
depletion of lymphocytes is not required under these
conditions.
The Journal of Thoracic aWithout the use of anti-Gal therapeutics, such as TPC,
graft survival is typically from a few days to weeks and is
accompanied by a large induction of anti-Gal antibodies at
the time of graft rejection.28 In this study no anti-Gal
antibodies were detected during the course of the transplan-
tation, and in the one animal that we were able to follow
after explantation, there was no induction of anti-Gal IgM or
IgG, although there was a gradual return to 40% of baseline
values for anti-Gal IgM over a 14-day period. Although
TPC is generally effective at controlling the effects of
anti-Gal antibody, it is unlikely to be 100% effective, and
the postexplantation return of anti-Gal IgM in recipient 7
would be consistent with an anti-Gal–mediated DXR. It is
interesting, however, that the survival outcomes in this
study are similar to those of recent transplantations using
donor pigs that lack the Gal epitope.29 In a pig-to-baboon
heterotopic transplantation protocol, Kuwaki and associ-
ates29 reported a median graft survival of 78 days (range,
59-179 days; n  5) if animals lost because of nonimmu-
nologic causes are excluded from the analysis. Although
their immunosuppressive protocol is distinct, by using
T-cell depletion and chronic costimulation blockade, both
the survival of the organs and the histology of the graft at
rejection showing microvascular thrombosis and ischemic
injury are consistent with our observations. The immuno-
histologic analysis of rejected Gal-deficient xenografts
showed antibody and complement deposition. We, too, ob-
serve antibody binding to vascular endothelial cells but find
less evidence of complement deposition. This suggests in-
directly that even in the absence of anti-Gal antibody (eg,
using Gal deficient donor organs), transgenic expression of
Figure 4. Serum anti-Gal antibodies in the one animal that sur-
vived organ removal on day 137. The graph depicts the fold
change in anti-Gal IgM and IgG relative to pretransplantation
baseline serum values. The day of organ explantation (137) is
indicated by an asterisk. TPC was administered every 3 days
before transplantation and after day 30. Daily TPC dosing was
given from days 0 to 30, as indicated by the horizontal arrows. The
duration of immunosuppression with tacrolimus and sirolimus is
indicated by a horizontal arrow extending from POD 6 to 151.human CD46 or other human complement regulatory pro-
nd Cardiovascular Surgery ● Volume 130, Number 3 844.e6
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generation of pigs that are transgenic for human comple-
ment regulatory proteins and lack the Gal epitope might be
of benefit. It is clear in this study that TPC can effectively
control anti-Gal responses under these conditions; however,
we expect that in a clinical context the use of Gal-deficient
donor organs would be preferable because their use would
simplify postoperative care.
The microvascular thrombosis and ischemic injury to the
myocardium we observed at rejection has been ascribed to
an antibody-induced endothelial cell activation, resulting in
the development of a prothrombotic vasculature.30 Consis-
tent with this hypothesis, we observe focal-to-diffuse ba-
boon IgM and IgG binding to the graft endothelium. Deter-
mination of the specificity of these antiendothelial cell
antibodies might help elucidate the mechanism of graft
failure and would facilitate strategies to diagnose DXR. We
have not observed a cellular infiltrate in cardiac xenografts
using histology or immunohistology. This is consistent with
our previous experience and that of others but is at odds
with in vitro data that suggest that a robust cellular immune
response will occur.31 Given that we do detect anti-pig IgG
antibody on some grafts, there is likely to be a T-cell compo-
nent to the xenograft rejection process that is not manifest as a
cellular infiltrate under these conditions. The inability to com-
pletely deplete B cells in lymph nodes with rituximab suggests
that therapy targeting T-cell help to the xenoreactive B cells
might further extend xenograft survival.
Perioperative thrombocytopenia and consumptive coagu-
lopathies have been reported after solid organ and cellular
xenotransplantation.32-35 These early coagulopathies have
been at least partially ascribed to the known molecular
incompatibilities of the coagulation cascade between pigs
and primates.36-38 As prophylactic therapy, we and others
have administered heparin17,33-35; however, our recent ex-
perience with warfarin sodium (Coumadin), low-molecular-
weight heparin, or combination therapy with aspirin and
clopidogrel (Plavix) did not support a role for anticoagula-
tion in prolonging cardiac xenograft survival. For that rea-
son, we omitted postoperative enoxaparin in this study and
saw no perioperative decreases in platelets levels, no evi-
dence of an induced thrombocytopenia after transplantation,
and no histologic evidence of systemic coagulopathies in
the recipient organs. This suggests that acute coagulopathies
might result from a strong rejection response and not nec-
essarily from molecular incompatibilities in coagulation
control.
In this study we observed 2 organ failures caused by
rupture of the atrium or ventricle. We and others have
observed such graft failures under a variety of immunosup-
pressive conditions, including with the use of systemic
anticoagulation. With echocardiographic monitoring, we
observe intrachamber blood stasis, particularly on the left
844.e7 The Journal of Thoracic and Cardiovascular Surgery ● Seside of the heart. Such stasis promotes thrombosis, which
likely contributes to thrombotic complications, such as cor-
onary embolism and myocardial infarction, as well as pul-
monary embolism. In addition, kinking of the anastomosis
caused by external or internal abdominal compression might
further restrict graft blood flow. These failures would not
occur after orthotopic transplantation. It remains possible,
however, that coagulation incompatibilities alone or in com-
bination with innate rejection, such as with pre-existing
non-Gal antibody, might contribute to such thrombosis,
although there is a paucity of evidence for such high levels
of pre-existing non-Gal antibody.39,40 Transgenic endothe-
lial cell expression of anticoagulants has been shown to
improve xenograft survival in the mouse-to-rat model, sug-
gesting that incorporation of similar genetic strategies in the
pig might alleviate problems with thrombosis and further
extend pig-to-primate cardiac xenograft survival.41
The median graft survival of more than 3 months in this
study with only 2 organ rejections is encouraging and sug-
gests that cardiac xenograft rejection can be largely con-
trolled with an immunosuppressive regimen consisting of
currently clinically available drugs, with the exception of
TPC. The limited evidence of renal impairment, the absence
of serious bacterial infections, and the absence of PTLD
suggest that this immunosuppressive regimen was not ex-
cessive compared with earlier cyclophosphamide-based reg-
imens. If a continued T cell–dependent antibody response
persists under these conditions, however, there remains a
variety of additional approaches, such as plasmapheresis,
costimulation blockage, coreceptor blockage, and others,
that could be used to augment this current regimen. Dupli-
cation of these results in the orthotopic life-supporting
model is an essential next step to fully gauge the effective-
ness of the current regimen.
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Histology
For histology, sections of the right and left ventricles were rou-
tinely processed and stained with hematoxylin and eosin. For
immunohistochemistry, biopsy samples were embedded in OCT
(Miles Laboratories, Inc, Elkhart, Ind), snap-frozen in isopentane
and dry ice, and cut on a cryostat into 4-m-thick sections. Before
staining, tissue sections were briefly air-dried, fixed with acetone,
and rinsed with 3 changes of PBS, pH 7.2. Sections were stained
for human IgM (DAKO, Glostrup, Denmark), human IgG
(DAKO), and human C5b neoantigen (Research Diagnostics Inc,
Flanders, NJ). Antibody binding was detected with appropriate
horseradish peroxidase–conjugated secondary antibodies and dia-
minobenzidine stain.
A semiquantitative grading system was used to describe the
pathologic observations. The grade of DXR was scored on the
basis of the percentage of total myocardium identified as damaged
by means of examination of hematoxylin and eosin–stained sec-
tions as follows: grade 1, 0% to 25%; grade 2, 26% to 50%; grade
3, 51% to 75%; and grade 4, greater than 75%. In its mildest form,
the damage was characterized by myocyte vacuolization and in-
terstitial edema, and its severest form was characterized by coag-
ulative necrosis. For immunohistochemistry, the deposition of
antibody or complement was separated into 2 components. First,
the distribution of staining was assessed on the basis of the
percentage of capillaries and small vessels staining and was given
a grade of 0 (none), F (focal; 1% to 25%), and D (diffuse; 26% to
100%). The intensity of staining was none (grade 0), mild (grade
1), moderate (grade 2), and marked (grade 3).
844.e9 The Journal of Thoracic and Cardiovascular Surgery ● SeAt the termination of the experiment, all animals underwent
complete autopsy.
Anti-Gal Enzyme-linked Immunosorbent Assay
Sera from blood samples were analyzed preoperatively and
once or twice each week postoperatively by means of enzyme-
linked immunosorbent assay for detection of -Gal antibodies.
Infectious Disease Management
Two days of perioperative intravenous antibiotics were given:
ciprofloxacin (10 mg/kg; Bayer Corp, West Haven, Conn) and
vancomycin (10 mg/kg; Abbott Laboratories, North Chicago, Ill),
both twice a day, and fluconazole (1.5 mg/kg once daily; Diflucan;
Pfizer Inc, New York, NY). Intravenous ganciclovir (10 mg/kg
twice daily; F. Hoffmann-LaRoche Inc, Nutley, NJ; target levels
5-6 ng/mL) and itraconazole (200 mg orally twice daily; Sporanox;
Janssen Pharmaceutical Inc, Titusville, NJ) were given prophylac-
tically for the duration of the experiment.
Blood cultures were done for a recipient temperature of greater
than 101.5°C, leukocytosis, or unexplained clinical deterioration.
Empiric therapy with twice-daily intravenous vancomycin (10
mg/kg) and cefepime (250 mg; Maxipime; Bristol-Myers Squibb,
Princeton, NJ) was begun pending blood culture results when
antibiotic therapy was guided by in vitro susceptibilities.
Statistical Analysis
The probability of graft failure as a function of time wasestimated by using Kaplan-Meier analysis.
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